Harbour BioMed

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company that discovers and develops novel antibody therapeutics for immunology, oncology, and other disease areas. The company uses proprietary technology platforms including Harbour Mice® (which generates fully human monoclonal antibodies), bispecific antibody technology (HBICE®), and AI-powered tools to build a pipeline of therapeutic candidates across inflammatory and immunology diseases, oncology, and weight management.